Scienture (SCNX) announces the U.S. Food and Drug Administration, FDA, has approved SCN-102, one of the products being developed by Scienture, ...

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company announced the FDA approved its new drug application for Arbli.

Despite having cardiovascular risk factors, asymptomatic aircraft pilots referred for medical screenings demonstrate favorable long-term outcomes and a low risk for major cardiac events.

The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium.  Arbli, an angiotensin II receptor ...

Imagine receiving a diagnosis that changes your life in an instant: hypertrophic cardiomyopathy, a heart condition that can strike without warning, claiming thousands of lives annually .

Athlete's Heart or Cardiomyopathy: The Diagnostic 'Grey Zones' A common clinical scenario faced by the sports cardiologist is the athlete exhibiting mild LVH in the range of 13–16 mm ...

HeartLung Technologies to debut its FDA designated "Breakthrough" AI technology (AutoChamberTM) at ACC 2025, offering lifesaving AI solutions for CVD prevention. Marlon Montes HeartLung Corporation +1 ...

HeartLung Technologies selected as a finalist and will compete at the ACC 2025 Innovation Pitch Challenge in Chicago. Marlon Montes HeartLung Corporation +1 310-510-6004 ... Visit us on social media: ...

A recent study has highlighted the sex-specific implications of myocardial fibrosis on mortality in patients with severe ...

A systematic review and meta-analysis identified factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents (ESAs).

These features were not seen in patients with hypertension. The conventional echocardiographic features of left ventricular hypertrophy and function did not permit distinction between hypertensive ...

Sirolimus, the active ingredient in Felycin-CA1, at a higher dose is used as an immunosuppressant in human patients receiving ...